References
- Wiener DC, Kaplan TB, Bravo-Iniguez CE, Miller J, Berkowitz AL, Jaklitsch MT. Paraneoplastic neuromyelitis optica spectrum disorder as presentation of esophageal adenocarcinoma. Ann Thorac Surg. 2018;105(3):e133–5. doi:10.1016/j.athoracsur.2017.10.01529455827
- Nakayama-Ichiyama S, Yokote T, Hiraoka N, et al. A paraneoplastic neuromyelitis optica spectrum disorder associated with a mature B-cell neoplasm. Leuk Res. 2011;35(7):e111–3. doi:10.1016/j.leukres.2011.02.01921397326
- Figueroa M, Guo Y, Tselis A, et al. Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4. JAMA Neurol. 2014;71(4):495–498. doi:10.1001/jamaneurol.2013.633124733266
- Al-Harbi T, Al-Sarawi A, Binfalah M, Dermime S. Paraneoplastic neuromyelitis optica spectrum disorder associated with stomach carcinoid tumor. Hematol Oncol Stem Cell Ther. 2014;7(3):116–119. doi:10.1016/j.hemonc.2014.06.00124954081
- Iorio R, Rindi G, Erra C, Damato V, Ferilli M, Sabatelli M. Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4. Mult Scler. 2015;21(6):791–794. doi:10.1177/135245851557224125716881
- Annus A, Bencsik K, Obal I, et al. Paraneoplastic neuromyelitis optica spectrum disorder: A case report and review of the literature. J Clin Neurosci. 2018;48:7–10. doi:10.1016/j.jocn.2017.10.03029133107
- Kon T, Ueno T, Suzuki C, et al. Aquaporin-4 antibody positive neuromyelitis optica spectrum disorder associated with esophageal cancer. J Neuroimmunol. 2017;309:38–40. doi:10.1016/j.jneuroim.2017.05.00928601284
- Sepulveda M, Sola-Valls N, Escudero D, et al. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler. 2018;24(13):1753–1759. doi:10.1177/135245851773191428920766
- Beauchemin P, Iorio R, Traboulsee AL, Field T, Tinker AV, Carruthers RL. Paraneoplastic neuromyelitis optica spectrum disorder: a single center cohort description with two cases of histological validation. Mult Scler Relat Disord. 2018;20:37–42. doi:10.1016/j.msard.2017.12.01229291482
- Frasquet M, Bataller L, Torres-Vega E, et al. Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.J. Neuroimmunol. 2013;263(1–2):145–147. doi:10.1016/j.jneuroim.2013.07.003
- Tanaka M, Yanagida H, Suzumura A. Treatment for paraneoplastic neuromyelitis optica spectrum disorder (NMOSD): probable effects of tocilizumab for both cancer and NMOSD. Mult Scler Relat Disord. 2018;20:82–83. doi:10.1016/j.msard.2017.12.00229353735
- Armagan H, Tuzun E, Icoz S, et al. Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: favorable response to cancer treatment. J Spinal Cord Med. 2012;35(4):267–269. doi:10.1179/2045772312Y.000000001822925754
- Ontaneda D, Fox RJ. Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder? Int J Neurosci. 2014;124(7):509–511. doi:10.3109/00207454.2013.85420824111490
- Cai G, He D, Chu L, Dai Q, Xu Z, Zhang Y. Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature. Int J Neurosci. 2016;126(7):660–668. doi:10.3109/00207454.2015.105448126010208
- Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. doi:10.1212/WNL.000000000000172926092914